NEW YORK (GenomeWeb) – Expedeon said today it has signed a supply and license agreement with Cell Guidance Systems for use of its Lightning-Link Rapid Biotin technology.

Cell Guidance Systems will use the technology for the development of its TRIFic (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays, which are intended for applications including the measurement of exosomes in plasma.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.